Non-Profit to Accelerate Development of Potential New Parkinson’s Drug
Non-profit to accelerate development of potential new Parkinson’s drug
UK-based charity, Parkinson’s UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson’s.
The funding, to be spread over a twelve-month period, will support final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.
lthough L-DOPA is the most effective drug for treating Parkinson's, its long-term use is often complicated by significantly disabling dyskinesias – or involuntary movements – reducing the beneficial effect of the drug. Dyskinesia affects millions of people around the world, with around half (40 to 50 per cent) of all people with Parkinson’s experiencing it after five years of taking L-DOPA.
Neurolixis will now carry out final pre-clinical development of NLX-112, including testing in advanced pharmacology models prior to advancing NLX-112 into clinical studies.
This is the second project funded by Parkinson’s UK’s Virtual Biotech initiative. Launched last year to combat the lost opportunities in drug discovery and early clinical development caused by the changing pharma landscape, the Virtual Biotech allows the charity to provide leadership and critical funding in partnership with a range of other organisations that have the facilities and staff to carry out scientific work on a contract basis.
Director of Research and Development at Parkinson’s UK, Dr Arthur Roach, said: “Being able to use our Virtual Biotech venture to accelerate the development of promising a new treatment that could potentially prevent L-DOPA-induced dyskinesia is very exciting for us and for people with Parkinson’s across the world.
“With dyskinesia, everyday tasks, such as eating, writing and walking, can become extremely difficult. In fact, two thirds of people with Parkinson’s have told us it is one of the most critical issues that impacts quality of life. With this new project, we hope to be able to deliver a potential treatment that will help address this global problem.”
NLX-112 was discovered and developed by French pharma company, Pierre Fabre Médicament, as a potential treatment for pain. After reaching phase two clinical trials, it was out-licensed to Neurolixis, which identified an opportunity to re-purpose the drug for the treatment of L-DOPA-induced dyskinesia.
Dr Roach continued: “Because this drug has already reached phase two clinical trials in the past, we already know a lot about its safety in humans. This means that, should this last pre-clinical study go well, we could be seeing a new treatment for Parkinson’s within as little as five years.
Dr Mark Varney, Co-founder, President and Chief Executive Officer at Neurolixis, said: “We greatly appreciate Parkinson’s UK supporting this program. This grant will now enable us to move the NLX-112 program through the necessary regulatory steps in preparation for clinical trials in Parkinson’s patients.”
This article has been republished from materials provided by Parkinson's Virtual Biotech. Note: material may have been edited for length and content. For further information, please contact the cited source.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
New Microscope Captures Detailed 3-D Movies of Cells Deep Within Living SystemsNews
Merging lattice light sheet microscopy with adaptive optics reveals the most detailed picture yet of subcellular dynamics in multicellular organisms.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018